Urine of patients with nephrotic syndrome contains the plasma type of PAF-acetylhydrolase associated with lipoproteins

Nephron - Physiology

Volumn 97, Issue 3, 2004, Pages

  Balafa, Olga C ^a   Karabina, Sonia Athena P ^b   Pappas, Charalambos A ^a   Elisaf, Moses ^a   Tselepis, Alexandros D ^b   Siamopoulos, Kostas C ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Lipiduria; Lipoproteins; Nephrotic syndrome; PAF acetylhydrolase; Proteinuria

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRICHLOROACETIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; ENZYMURIA; FEMALE; GLOMERULONEPHRITIS; HUMAN; HYDROLYSIS; MALE; NEPHROTIC SYNDROME; PRECIPITATION; PRIORITY JOURNAL; PROTEINURIA; URINALYSIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NEPHROTIC SYNDROME;

EID: 4043077002     PISSN: 16602137     EISSN: None     Source Type: Journal    
DOI: 10.1159/000078645     Document Type: Article

References (25)

1. Imaizumi TA, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA: Platelet-activating factor: A mediator for clinicians. J Intern Med 1990;238:5-20.
2. Bussolino F, Camussi G, Baglioni C: Synthesis and release of PAF by human vascular endothelial cells treated with IL-1β and TNF-α. J Biol Chem 1998;263:11856-11861.
3. Schlondorff D, Goldwasser P, Neuwirth R, Satriano JA, Clay K: Production of platelet-activating factor in glomeruli and cultured glomerular cells. Am J Physiol 1986;251:F1123-F1127.
4. Perico N, Lapinski R, Konopka K, Aiello S, Noris M, Remuzzi G: Platelet-activating factor mediates angiotensin-induced proteinuria in isolated perfused rat kidney. J Am Soc Nephrol 1997;3:1391-1398.
5. Schlondorff D, Neuwirth R: Platelet-activating factor and the kidney. Am J Physiol 1986;251:F1-F11.
6. Jocks T, Freudenberg J, Zahner G, Stahl RAK: Platelet-activating factor mediates monocyte chemoattractant protein-1 expression in glomerular immune injury. Nephrol Dial Transplant 1998;13:37-43.
7. Camussi G, Tetta C, Coda R: Platelet-activating factor induced loss of glomerular anionic charges. Kidney Int 1984;25:73-81.
8. Lianos E, Zanglis A: Glomerular platelet-activating factor levels and origins in experimental glomerulonephritis. Kidney Int 1990;37:736-740.
9. Iatrou C, Moustakas G, Antonopoulou S, Demopoulos C, Ziroyiannis P: Platelet-activating factor levels and PAF acetylhydrolase activities in patients with primary glomerulonephritis. Nephron 1996;72:611-616.
10. Noris M, Benigni A, Boccardo P, Gotti E, Benfennati E, Aiello S, Remuzzi G: Urinary excretion of platelet-activating factor in patients with immune-mediated glomerulonephritis. Kidney Int 1993;43:426-429.
11. 2, platelet-activating factor acetylhydrolase. Atherosclerosis 2002;suppl 3:57-68.
12. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor acetylhydrolases. J Biol Chem 1997;272:17895-17898.
13. Milionis H, Elisaf M, Karabina SAP, Bairaktari E, Tselepis AD, Siamopoulos KC: Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures. Kidney Int 1999;56:2276-2285.
14. Tjoelker LW, Stafforini DM: Platelet-activating factor acetylhydrolases in health and disease. Biochim Biophys Acta 2000;1488:102-123.
15. Kirschbaum B: Platelet-activating factor acetylhydrolase activity in the urine of patients with renal disease. Clin Chim Acta 1991;199:139-146.
16. Tsimihodimos V, Karabina SAP, Tambaki AP, Bairaktari E, Miltiadous G, Goudevenos JA, Cariolou MA, Chapman MJ, Tselepis AD, Elisaf M: Altered distribution of PAF-acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia. J Lipid Res 2002;43:256-263.
17. Tselepis AD, Dentan C, Karabina SAP, Chapman J, Ninio E: PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VLDL-1 in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1764-1773.
18. Shore VG, Forte T, Licht H, Lewis SB: Serum and urinary lipoproteins in the human nephrotic syndrome: Evidence for renal catabolism of lipoproteins. Metabolism 1982;31:258-268.
19. Streather CP, Vargese Z, Moorhead JF, Scoble JE: Lipiduria in renal disease. Am J Hypertens 1993;6:353S-357S.
20. Douchet C, Mooser V, Gonbert S, Raymond F, Chapman J, Jacobs C, Thillet J: Lipoprotein(a) in the nephrotic syndrome. Molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine. J Am Soc Nephrol 2000;11:507-513.
21. Wheeler D, Chana R, Topley N, Petersen M, Davies M, Williams J: Oxidation of low density lipoprotein by mesangial cells may promote glomerular injury. Kidney Int 1994;44:1628-1636.
22. Kamanna V, Pai R, Ha H, Kirschenbaum M, Roh D: Oxidised low density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int 1999;55:2192-2202.
23. Tanaka R, Iijima K, Xu H, Inoue Y, Muramari R, Shirakawa T, Nishiyama K, Miwa M, Shiozawa S, Nakamura H, Yoshikawa N: Role of platelet-activating factor aceylhydrolase gene mutation in Japanese childhood IgA nephropathy. Am J Kidney Dis 1999;34:289-295.
24. Tsimihodimos V, Kakafika A, Tambaki AP, Bairaktari E, Chapman MJ, Elisaf M, Tselepis AD: Fenofibrate induces HDL-associated PAF-acetylhydrolase but attenuates enzyme activity associated with apoB-containing lipoproteins. J Lipid Res 2003;44:927-934.
25. Mertens A, Holvoet P: Oxidized LDL and HDL: Antagonists in atherothrombosis. Faseb J 2001;15:2073-2084.